“Accent Therapeutics Inc. will receive $55 million up front and as much as $1.1 billion in milestones as part of a substantial new three-molecule deal with Astrazeneca plc, which committed to exploring what Astrazeneca’s oncology chief, José Baselga, called the "compelling" field of targeting RNA-modifying proteins (RMPs) for the treatment of cancer.”

[link to www.bioworld.com (secure)]

Nothing to see here.
.